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diac anomalies,1,7 and relatively small experience in
each institute.2,4 However, more favorable clinical
results have been obtained over the last 2 decades.8-10 In
the present study, we reviewed a 20-year experience
with the surgical treatment of mitral valve disease in the
pediatric age group at our institution with 2 objectives:
to clarify the long-term results over the last 2 decades
and to evaluate the recent advances in mitral valve oper-
ation in children. 
Patients and methods 
Patient population. From December 1978 to September
1998, 56 patients underwent a total of 36 mitral valve repairs
and 30 mitral valve replacements. Fifty-two patients had pre-
dominant mitral incompetence (MI), and 4 patients had pre-
S urgery for mitral valve disease in infants and chil-dren has been a major therapeutic challenge for
many years.1-4 It poses special clinical and technical
difficulties that include a wide spectrum of morpholog-
ic abnormalities,5,6 a high prevalence of associated car-
Objectives: We reviewed a 20-year experience with the surgical treatment
of mitral valve disease in the pediatric age group at our institution with
2 objectives: to clarify the long-term results over the last 2 decades and
to evaluate the recent advances in mitral valve operation in children.
Methods: Since December 1978, 56 patients have undergone a total of 36
mitral valve repairs and 30 mitral valve replacements. Associated car-
diac anomalies were present in 46 patients (82%), and concurrent repair
of associated lesions was performed in 37 patients (66%). The age of the
patients ranged from 3 months to 15 years (mean, 3.6 years) at mitral
valve repair, and ranged from 2 months to 16 years (mean, 5.7 years) at
mitral valve replacement. Mean follow-up period was 92.0 months
(range, 1-235 months). Results: There were 2 hospital deaths and 2 late
deaths in patients who underwent mitral valve repair. Reoperation was
performed in 4 patients. Three of these patients underwent mitral valve
replacement because of residual mitral incompetence. No hospital
deaths occurred in patients who underwent mitral valve replacement.
Two late deaths occurred after mitral valve replacement. Six patients
had a total of 10 episodes of prosthetic valve thrombosis. Thrombolytic
therapy with urokinase was successful in all episodes without serious
complications. Five patients required reoperations 49 to 141 months
(mean, 78.4 months) after the initial valve replacement for relative pros-
thetic valve obstruction as the result of somatic growth. A valve 2 or 3
sizes larger than the original prostheses was inserted without death.
Actuarial survival and freedom from cardiac events at 10 years after the
operation were 87.2% and 72.7% in children who underwent mitral
valve repair, and 90.3% and 67.3% for those children who underwent
mitral valve replacement. Conclusions: The current risk of mitral valve
operation in the pediatric age group is low, and the long-term results are
satisfactory, irrespective of severe deformation of the mitral valve appa-
ratus and associated complex cardiac anomalies. (J Thorac Cardiovasc
Surg 1999;118:99-106)
Naoki Yoshimura, MDa
Masahiro Yamaguchi, MDa
Yoshihiro Oshima, MDa
Shigeteru Oka, MDa
Yoshio Ootaki, MDa
Hirohisa Murakami, MDa
Teruo Tei, MDb
Kyoichi Ogawa, MDa
From the Departments of Cardiothoracic Surgerya and Cardiology,b
Kobe Children’s Hospital, Kobe, Japan.
Received for publication Dec 1, 1998; revisions requested Jan 26,
1999; revisions received Feb 26, 1999; accepted for publication
March 15, 1999.
Address for reprints: Naoki Yoshimura, MD, Department of
Cardiothoracic Surgery, Kobe Children’s Hospital, 1-1-1,
Takakura-dai, Suma-ku, Kobe, 654-0081 Japan.
Copyright © 1999 by Mosby, Inc.
0022-5223/99 $8.00 + 0 12/1/98585
99
SURGERY FOR MITRAL VALVE DISEASE IN THE PEDIATRIC AGE GROUP
dominant mitral stenosis. Associated cardiac anomalies were
present in 46 patients (82%; Table I). Left atrioventricular
valve anomalies associated with atrioventricular discordance
and the initial definitive repair of the atrioventricular canal
were excluded from this study. Fourteen patients had under-
gone previous operations. Nine patients had undergone atri-
oventricular canal repair; 2 patients had undergone coarcta-
tion repair; 2 patients had undergone pulmonary artery
banding, and 1 patient had undergone repair of total anom-
alous pulmonary venous drainage.11 Concurrent repair of
associated lesions was performed in 37 patients (66%). These
included repair of complex cardiac anomalies in 3 patients, 2
of whom required total cavopulmonary anastomosis, along
with a double switch operation. Cardiopulmonary bypass and
systemic hypothermia (12.8°C to 31.5°C) were used for all
procedures. Deep hypothermic circulatory arrest was used for
6 operations before 1983. Cold blood cardioplegia with topi-
cal cardiac cooling through a median sternotomy was used in
46 operations in which concomitant operative procedures
were performed. Hypothermic ventricular fibrillation through
a right lateral thoracotomy was used in 20 isolated mitral
valve operations. 
Mitral valve repair. The ages of the patients at the mitral
valve repair ranged from 3 months to 15 years (mean ± SD,
3.6 ± 3.1 years); body weight ranged from 5.1 to 55.8 kg
(12.7 ± 8.7 kg). Seven patients were younger than 1 year of
age. The pathologic findings of the mitral valve apparatus are
listed in Table II. Annular dilatation was the most common
anatomic lesion (30 patients), followed by prolapsed leaflet
(24 patients), elongated chordae (13 patients), or papillary
muscle (9 patients). A list of procedures is detailed in Table
III. Because malformation usually implies several anomalies,
several techniques were used in the same patient. Reed annu-
loplasty was the method of annular repair.12 Prosthetic ring
annuloplasty was not used. Cleft leaflet was corrected by a
direct suture technique. Prolapse of a leaflet was corrected by
redundant valvular tissue removal, chordal shortening, artifi-
cial chordae,13 or papillary muscle shortening.8 More recent-
ly, we prefer the papillary muscle shortening with split and
tuck-in technique (Fig 1). 
Mitral valve replacement. Mitral valve replacement was
indicated in patients with severe valvular deformities not
amenable to repair (Fig 2). There was no difference in the
prevalence of mitral valve replacement between the first and
second decades (Fig 3). The age of the patients at mitral valve
replacement ranged from 2 months to 16 years (5.7 ± 5.0
years); body weight ranged from 4.2 to 84.7 kg (18.5 ± 17.7
kg). Five patients were younger than 1 year of age. Prosthetic
valves that were implanted included 21 St Jude Medical (17
mm HP in 1 patient, 19 mm in 2 patients, 21 mm in 2
patients, 23 mm in 6 patients, 25 mm in 4 patients, 27 mm in
2 patients, 29 mm in 1 patient, and 33 mm in 2 patients; St
Jude Medical, Inc, St Paul, Minn), 4 CarboMedics (25 mm in
1 patient, 27 mm in 2 patients, and 31 mm in 1 patient; Sulzer
Carbomedics, Inc, Austin, Texas), 3 Björk-Shiley (17 mm, 19
mm, 23 mm; Shiley, Inc, Irvine, Calif), and 2 ATS (23 mm,
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Table I. Associated cardiac anomalies (46 patients, 82%)
Type of lesion Patients (n)
Ventricular septal defect 18
Common atrioventricular canal 9
Atrial septal defect 3
Atrial septal defect + ventricular septal defect 3
Coarctation complex 2
Double outlet right ventricle 2
Aortic stenosis 2
Aortic insufficiency 1
Total anomalous pulmonary venous drainage 1
Bland-White-Garland 1
Bland-White-Garland + ventricular septal defect 1
Tricuspid atresia 1
Univentricular heart 1
Atrial septal defect + partial anomalous pulmonary 1
venous drainage
Table II. Mitral valve lesions in patients who under-
went mitral valve repair
Type of lesion n
Supravalvular stenosing ring 1
Valve
Prolapsed leaflet 23
Cleft anterior leaflet 6
Commissure fusion 1
Anulus
Annular dilatation 30
Chordae
Elongated chordae 13
Short chordae 4
Cordal rupture 2
Papillary muscle
Elongated papillary muscle 8
Hypertrophied or calcified papillary muscle 3
Table III. Technique of mitral valve repair
Technique of repair n
Resection of supravalvular stenosing ring 1
Valve
Redundant valvular tissue removal 14
Closure of cleft 6
Commissurotomy 1
Anulus
Annuloplasty 30
Chordae
Chordal shortening 8
Artificial chordae 3
Papillary muscle
Papillary muscle shortening: split & tuck in 9
Papillary muscle shortening: split & basal sling 1
Papillary muscle splitting 3
29 mm; ATS Medical, Inc, Minneapolis, Minn). The prosthe-
sis was placed in a conventional manner within the native
anulus in all patients. All patients with prosthetic valves were
anticoagulated with warfarin sodium (Coumadin). The crite-
rion for adequate anticoagulation state with warfarin was
considered 15% to 35% in the thrombotest. More recently,
antiplatelet agent (aspirin or dipyridamole) has been admin-
istered in combination with warfarin sodium.
Follow-up. Fifty-three operative survivors were followed
through clinic visits. Two patients were lost to follow-up at
56 months and 100 months. The mean follow-up period was
92.0 months (range, 1-235 months), and the end of the fol-
low-up study was September 30, 1998. Kaplan-Meier sur-
vival analysis was used to evaluate the survival and freedom
from cardiac events. Cardiac events include cardiac death,
structural and nonstructural valve dysfunction, need for reop-
eration, thromboembolism and bleeding, or valvular endo-
carditis. These events were defined in agreement with the
reporting on cardiac valvular operations guidelines.14
Results
Early results 
Mitral valve repair. Two hospital deaths (5.6%)
occurred in patients who underwent mitral valve repair.
An 11-month-old infant who underwent an operation in
1980 died of multiple organ failure caused by medias-
tinitis. The second death was in an infant with active
infective endocarditis who underwent mitral valve
repair on an emergency basis for progressive heart fail-
ure. This patient died of sepsis and disseminated
intravascular coagulation on postoperative day 9. One
patient who underwent mitral annuloplasty, triangular
resection of the anterior leaflet, and shortening of the
papillary muscle with concomitant closure of ventricu-
lar septal defect had severe residual MI and required
valve replacement 56 days after the reparative opera-
tion. Among patients not having reoperation, cardiac
catheterization was performed in 28 patients before
discharge from hospital. Left ventriculogram showed
grade 2 MI in 3 patients and grade 1 in 12 patients. The
other 13 patients had no MI. 
Mitral valve replacement. No hospital deaths
occurred in this series. All patients who underwent
valve replacement had marked clinical improvement
and relief of congestive heart failure. Unilateral throm-
bosed leaflet of a bileaflet mechanical valve occurred
in 5 patients before discharge from the hospital (Table
IV). A 5-month-old infant showed signs of low cardiac
output 17 days after the mitral valve replacement; the
other 4 patients were asymptomatic and were diag-
nosed during routine checkup. Thrombolytic therapy
with urokinase was performed each time, and the
thrombus was successfully dissolved. Initial dose of
urokinase ranged from 500 to 18,000 U/kg/hr, and
maximum dose ranged from 2600 to 18,000 U/kg/hr.
The duration of treatment ranged from 8 to 14 days.
Four patients experienced bleeding complications, and
1 patient required blood transfusion during the throm-
bolytic therapy. Two of the 5 patients with complicated
unilateral thrombosed leaflet showed poor left ventric-
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Fig 1. Papillary muscle shortening: split and tuck-in technique.
The excess length of the chorda is tucked into a longitudinal
split made in the top of the papillary muscle and sutured.
Fig 2. A rare case with supravalvular stenosing ring and pap-
illary muscle agenesis. In patients with gross deformities of
the mitral valve apparatus in which no conservative surgical
treatment is feasible, mitral valve replacement should be con-
sidered the procedure of choice.
ular function (left ventricular ejection fraction, 49.2%
and 43.5%). 
Late results 
Mitral valve repair. There were 2 late deaths among
the 33 patients who survived the initial mitral valve
repair. One patient who underwent valve replacement
56 days after the reparative operation died of prosthet-
ic valve dysfunction. Death occurred 13 months after
mitral valve replacement. Another patient died of
chronic renal failure 28 months after mitral valve
repair. Actuarial survival was 87.2% (95% confidence
limits [CL], 75.3%-99.1%) at 10 years in children who
underwent mitral valve repair (Fig 4). 
Reoperation was performed in 3 patients. Two of
these patients underwent mitral valve replacement
because of residual MI 3 and 64 months after the repar-
ative operation, respectively. Another patient who
underwent mitral annuloplasty, triangular resection of
the anterior leaflet, and closure of ventricular septal
defect experienced the development of mitral stenosis.
The patient required open mitral commissurotomy and
mitral valve replacement 43 and 141 months after the
initial operation, respectively. Among the long-term
survivors without reoperation, 8 patients had a grade
1/6 or 2/6 systolic murmur. Echocardiography showed
trivial to mild MI. All surviving patients were free of
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Fig 3. The numbers of mitral valve repair and mitral valve replacement by operation year.
Table IV. Thrombolytic therapy for the prosthetic valve thrombosis
Time from Maximum dose 
Age at MVR Clinical of UK Duration of 
Patient MVR Prosthesis to event presentation (U/kg/hr) treatment (d) Complications
1 9 y SJM (33 mm) 7 mo Cerebellar infarction 1,000 5 No
2 1 y SJM (23 mm) 11 d Asymptomatic 2,600 10 Hematuria
13 mo Vomiting 2,900 13 Subcutaneal hemorrhage
29 mo New murmur 1,700 10 No
3 5 m SJM (19 mm) 17 d LOS 18,000 10 Hematoma; blood transfusion
4 3 y SJM (25 mm) 1 mo Asymptomatic 4,000 8 Subcutaneal hemorrhage
2 mo Asymptomatic 3,000 12 No
3 mo Asymptomatic 2,000 4 No
5 4 y CM  (25 mm) 1 mo Asymptomatic 3,000 12 No
6 5 y ATS (23 mm) 26 d Asymptomatic 10,500 14 Subcutaneal hemorrhage; 
nasal bleeding
MVR, Mitral valve replacement; SJM, St Jude Medical; LOS, low cardiac output syndrome; CM, Carbomedics; ATS, ATS Medica; UK, urokinase.
symptoms. Actuarial freedom from cardiac events was
72.7% (95% CL, 54.0%-91.5%) at 10 years in children
who underwent mitral valve repair (Fig 5). 
Mitral valve replacement. There were 2 late deaths as
a result of prosthetic valve dysfunction in 1 patient
(mentioned previously) and sepsis in another patient.
Deaths occurred from 14 to 83 months after mitral
valve replacement. Actuarial survival was 90.3% (95%
CL, 77.0%-100%) at 10 years in children who under-
went mitral valve replacement (Fig 4). 
Among the 25 patients who underwent mitral valve
replacement, 5 patients outgrew their prosthetic valve
and underwent a repeat valve replacement 49, 49, 56,
97, and 141 months after the initial valve replacement,
respectively. The age, body weight, body surface area,
and prosthetic valve size at the initial and second valve
replacements are shown in Table V. Two of the 5
patients underwent initial valve replacement at the age
of less than 1 year with the use of a 19-mm Björk-
Shiley prosthesis (Shiley, Inc) and a 19-mm St Jude
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Fig 4. Actuarial survival (including hospital deaths) of patients who underwent mitral valve repair (solid line) and
mitral valve replacement (dotted line).
Fig 5. Freedom from cardiac events (including hospital deaths and morbidity) of patients who underwent mitral
valve repair (solid line) and mitral valve replacement (dotted line).
Medical prosthesis (St Jude Medical, Inc). The body
surface area of the 2 patients doubled from 0.30 and
0.33 m2 at the initial operation to 0.66 and 0.63 m2 at
the time of repeat valve replacement. In 4 patients a
valve 2 sizes larger and in 1 patient a valve 3 sizes larg-
er than the original prostheses were inserted (Table V).
Second valve replacement was safely performed with
no deaths.
Unilateral thrombosed leaflet of a bileaflet prosthesis
occurred in 3 patients between 2 and 29 months after
operation (Table IV). These 3 patients underwent anti-
coagulation with warfarin and antiplatelet agents and
were maintained by the thrombotest between 20% and
30%. Thrombolytic therapy with urokinase was per-
formed as the first line of treatment for a thrombosed
valve. Maximum dose ranged from 1000 to 3000
U/kg/hr, and the duration of treatment ranged from 5 to
13 days. A transient subcutaneous hemorrhage occurred
in 1 patient during the thrombolytic therapy. Successful
thrombolysis was achieved in these 3 patients, and
none of these patients required subsequent operation.
Actuarial freedom from cardiac events was 67.3%
(95% CL, 49.3%-85.2%) at 10 years in children who
underwent mitral valve replacement (Fig 5). 
Discussion
This report describes our 20-year experience with
operations for mitral valve disease in children in an
attempt to assess the clinical course of patients in terms
of valve-related problems in this special age group.
There have been several reports of operations for con-
genital mitral valve malformations in the pediatric age
group.1-4,7-10 Early and late deaths in small children
with mitral valve disease has been high, particularly for
those children with valve replacement.4,15,16 Kadoba
and coworkers15 reported 9 early deaths in 25 patients
(36%) with mitral valve replacement in the first year of
life. Zweng and coworkers4 described the results of
mitral valve replacement in 19 children younger than 5
years of age. There were 6 early deaths (32%) and 3
late deaths (16%). This special age group of patients
poses unique problems that include the small size of
mitral anulus, a wide spectrum of valvular lesions and
relatively small experience,4-6 a high prevalence of
associated cardiac anomalies that often complicate the
perioperative course,1,7 a relative stenosis of the pros-
thesis as the result of tissue overgrowth or somatic
growth,15-18 and difficulties associated with anticoagu-
lant therapy.19 Although surgical management of con-
genital malformations of the mitral valve in the pedi-
atric age group remain a therapeutic challenge,
especially in patients with mitral stenosis or infants
younger than 1 year of age described in series by
Kadoba and colleagues15 and Zweng and colleagues,4
recent reports of mitral valve operation in the pediatric
age group have been encouraging, with decreased mor-
bidity and early and late deaths.8-10 Because limited
information is available concerning the recent advances
in mitral valve operation in children, we reviewed our
institutional experience with mitral valve operation in
children over the past 2 decades. The early mortality
rate was 3.6% (2/56 patients), and the late mortality rate
was 5.6% (3/54 patients, including 2 patients with non-
cardiac death). Our experience demonstrates that the
current operative risk of mitral valve operation is low,
irrespective of severe deformation of the mitral valve
apparatus and associated complex cardiac anomalies. 
Mitral valve repair was initially performed in 35 of
56 patients. Long-term results compare favorably with
those after mitral valve replacement. Mitral valve
repair offers the advantages of the avoidance of throm-
boembolism, the preservation of chordal function, and
a potentially reduced need for reoperation. Because of
the wide spectrum of lesions, which characteristically
involved multiple components of the valvular appara-
tus,5 multiple techniques of valve repair are
required.1,8,9,13 In the present study, annular dilatation
and prolapsed leaflet were the most frequent lesions.
Annuloplasty was performed in all patients with annu-
lar dilatation irrespective of mitral valve disease. The
method of annular repair consisted of Reed annulo-
plasty.12 No rigid rings were used so as not to interfere
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Table V. Redo mitral valve replacement
Body weight Body surface area 
Patient Age (kg) (m2) Prosthesis
1 6 m fi 4y7m 5.3 fi 14.2 0.30 fi 0.66 B-S (19 mm) fi SJM (25 mm)
2 1 y fi 5y2m 6.7 fi 16.1 0.35 fi 0.67 B-S (17 mm) fi SJM (21 mm)
3 4y6m fi 16y3m 14.9 fi 84.7 0.69 fi 1.93 SJM (23 mm) fi CM (27 mm)
4 3 y fi 11y1m 11.9 fi 42.3 0.56 fi 1.28 SJM (25 mm) fi ATS (29 mm)
5 5 m fi 5y1m 5.5 fi 14.2 0.33 fi 0.63 SJM (19 mm) fi ATS (23 mm)
B-S, Björk-Shiley; SJM, St Jude Medical; CM, Carbomedics; ATS, ATS Medical.
with the growth of the heart and to avoid thromboem-
bolism. We presently treat mitral valve prolapse by
redundant valvular tissue removal, artificial chordae,13
and/or papillary muscle shortening with the split and
tuck-in technique. These techniques provided sympto-
matic relief and long-term durability of the results in
most of the patients. 
Although conservative procedures are obviously
preferable and should be considered the procedures of
choice, morphologic condition greatly influences the
difficulty of conservative surgical treatment for con-
genital mitral valve disease in the pediatric age group.
We encountered many valves significantly lacking in
valve tissue and also having other severe deformation
of the subvalvular apparatus that rendered reconstruc-
tion impossible.20 In patients with gross deformities of
the mitral valve apparatus in which no conservative
surgical treatment is feasible, mitral valve replacement
should be considered the procedure of choice. In our
experience, mitral valve replacement in children can be
performed safely with no hospital death. Although
prosthetic valve replacement was not associated with
any operative deaths in this series, the major problems
with valve replacement in children are long-term sur-
vival and valve-related complications.15-17,21
Mitral valve replacement in children carries the dis-
advantage of requiring repeat valve replacement.15-16 In
our experience, 5 patients required reoperations for rel-
ative prosthetic valve obstruction because of somatic
growth. It is well known that the anulus of the mitral
valve will grow even when fixed to a prosthetic valve
sewing ring, thereby permitting the use of a larger-
sized valve at the time of repeat valve replace-
ment.15,16,18 A valve 2 or 3 sizes larger than the original
prostheses was inserted in our patients. Indications and
timing for repeat valve replacement have not been
established. Kadoba and associates15 performed repeat
mitral valve replacement on several patients with com-
plicated acute pulmonary edema or circulatory collapse
on an emergency basis. We consider it essential that the
prosthetic valve function and hemodynamic parameters
are re-evaluated when the body surface area of the
patients achieve twice that at the initial operation espe-
cially in patients in whom mitral valve replacement
was performed before the age of 1 year. We believe that
elective second valve replacement can be performed
safely and provide extended palliation for many years. 
Prosthetic valve thrombosis is one of the most fre-
quent complications after valve replacement opera-
tion.19,21 A second surgical procedure with debridement
or valve replacement has been the traditional method of
management. Since Luluaga and colleagues22 first
reported the successful treatment of a prosthetic valve
thrombosis in the tricuspid position with thrombolytic
therapy, several cases receiving thrombolytic therapy
have been reported, and this approach has become a
promising alternative to valve replacement.23-26
However, to our knowledge, no series of thrombolytic
therapy as first-line therapy for prosthetic valve throm-
bosis in the pediatric age group has been reported. Since
our first experience with thrombolytic treatment of a
thrombosed St Jude Medical valve, we have used this
approach as our first-line therapy for prosthetic valve
thrombosis. Since 1990, 6 patients had a total of 10
episodes of prosthetic valve thrombosis. The incidence
of prosthetic valve thrombosis for patients who under-
went operation in our institution is relatively high, prob-
ably because a larger-sized prosthesis was implanted in
children in consideration of their somatic growth.
Thrombus formation may occur easily because blood
flow through the prosthesis is low in children. Poor left
ventricular function might be one of the causative fac-
tors of prosthetic valve thrombosis. However, most
patients could be stabilized hemodynamically because
large-sized bileaflet prostheses continued to allow blood
flow, which could avoid an emergency operation or
sudden death and provide time for an accurate diagno-
sis. Diagnosis was established, and the treatment was
monitored by echocardiography and cinefluoroscopy.
All patients were treated with a urokinase loading dose
of about 2500 to 3500 U/kg/hr. If necessary, the infu-
sion was subsequently increased to a maximum dose of
18,000 U/kg/hr. Joyce and colleagues25 reported that
children required a larger dose of urokinase than that
required for adults because plasminogen levels are
lower in children. Thrombolytic therapy was successful
in all episodes without serious complications. We
believe that thrombolytic therapy can be used as the
first-line therapy in children with prosthetic valve
thrombosis.
In summary, we reviewed a 20-year experience with
the surgical treatment of mitral valve disease in the
pediatric age group at our institution. Thirty-six mitral
valve repairs were performed in 35 patients. Two early
deaths occurred in patients younger than 1 year of age.
Actuarial survival and freedom from cardiac events at
10 years were 87.2% and 72.7%, respectively. Although
mitral valve repair should be considered the procedure
of choice, mitral valve replacement should be consid-
ered as the procedure of choice in patients with gross
deformities of the mitral valve apparatus. Thirty mitral
valve replacements in 25 children were performed safe-
ly with no hospital deaths. Actuarial survival and free-
dom from cardiac events at 10 years were 90.3% and
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67.3%, respectively. Thus we conclude that the current
operative risk of mitral valve operation is low, irrespec-
tive of severe deformation of the mitral valve apparatus
and associated complex cardiac anomalies.
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